- 产品描述
- 产品组分
- 文件资源
- 营销中心
- 注意事项
- FAQ
- 文献追踪
-
DiscoveryProbe™ FDA批准的药物库包括2320种FDA批准的药物，用于高通量筛选（HTS）和高含量筛选（HCS）。它可用于为老药寻找新的目标。这些药物的生物活性和安全性已被临床试验所证实。由于它们都是FDA批准的药物，所筛选的药物可以直接用于临床试验。
Catalog No. Product Name Summary Targets CAS Number Smiles A3298 Cetirizine Antihistamine Neuroscience|Histamine Receptor 83881-51-0 C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl A3789 Salmeterol xinafoate β2-adrenergic receptor agonist GPCR/G protein|Adrenergic Receptor 94749-08-3 C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O.C1=CC=C2C(=C1)C=CC(=C2O)C(=O)O A4363 Fluvastatin Sodium HMG-CoA reductase inhibitor Metabolism|HMG-CoA Reductase 93957-55-2 CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+] A4370 Moclobemide (Ro 111163) Reversible inhibitor of MAO-A Metabolism|MAO 71320-77-9 C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl A8252 Nintedanib(BIBF 1120) VEGFR/PDGFR/FGFR inhibitor Tyrosine Kinase/Adaptors|PDGFR 928326-83-4 CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)NC(=C3C4=C(C=C(C=C4)C(=O)OC)NC3=O)C5=CC=CC=C5 B1792 Montelukast Sodium Leukotriene receptor antagonist GPCR/G protein|CysLT1 receptor 151767-02-1 CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)[O-])O.[Na+] N1674 Piperine MAPK inhibitor Natural Products 94-62-2 C1CCN(CC1)C(=O)C=CC=CC2=CC3=C(C=C2)OCO3 N1707 Coumarin Precursor in chemical reaction Natural Products 91-64-5 C1=CC=C2C(=C1)C=CC(=O)O2 Form Pre-dissolved DMSO solutions Stability Solution: -20°C for 12 months, -80°C for 24 months Packaging 96-well Microplate format with peelable foil seal and EVA cap (20 μL/well, 10 mM DMSO);
96-well DeepWell format with peelable foil seal and EVA cap (100 μL/well, 10 mM DMSO);
96-well rack with Matrix 2D Barcoded ScrewTop Storage tubes (250 μL or 100 μL/well, 10 mM DMSO).Shipping Condition Evaluation sample solution: ship with blue ice
All other available size: ship with RT, or blue ice upon request1. Barrows NJ, Campos RK, Powell ST, et al. A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. Cell Host Microbe. 2016 Jul 27. pii: S1931-3128(16)30303-1.
Abstract
We interrogated a FDA-approved chemicals library for their ability to block infection of human HuH-7 cells by a newly isolated ZIKV strain (ZIKV MEX_I_7). In our in vitro screening assay, more than 20 out of 774 tested compounds reduced ZIKV infection. Then these compounds were further validated for inhibition of ZIKV infection in human neural, cervical and placental stem cell lines, as well as primary human amnion cells. We found that others that had no previously known antiviral activity (e.g., daptomycin) and anti-flaviviral drugs (e.g., bortezomib and mycophenolic acid) were identified as inhibitors of ZIKV infection. There were several drugs that reduced ZIKV infection across multiple cell types, which could be tested in clinical studies of ZIKV infection and provided small molecules to study ZIKV pathogenesis.2. Stavrovskaya IG, Narayanan MV, Zhang W, et al. Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J Exp Med. 2004 Jul 19;200(2):211-22.
Abstract
Mitochondria are a major checkpoint in several pathways leading to neuronal cell death and the mitochondrial permeability transition (mPT) may be critical in stroke-related injury. In order to prove this hypothesis, 1,040 FDA-approved drugs and other bioactive compounds were tested as potential mPT inhibitors. We found that 28 structurally related drugs, including tricyclic antipsychotics and antidepressants, capable of delaying the mPT. Clinically achievable doses of promethazine inhibited mPT and were protective in both in vitro and mouse models of stroke. Also, promethazine protected primary neuronal cultures subjected to oxygen-glucose deprivation and reduced neurological impairment and infarct size in mice subjected to middle cerebral artery occlusion/reperfusion. These results provided a class of safe, tolerable drugs for stroke and neurodegeneration and also provided new tools for understanding mitochondrial roles in neuronal cell death. -
产品组分
内容
型号
规格 价格 储存温度
IVDPlus 经FDA验证的药物库 L1021-01 20ul/孔（10mM 溶液）/96微孔板 0.00 -20°C IVDPlus 经FDA验证的药物库 L1021-02 100ul/孔（10mM 溶液）/96深孔板 0.00 -20°C IVDPlus 经FDA验证的药物库 L1021-03 100ul/孔（10mM 溶液）/带盖96孔板 0.00 -20°C IVDPlus 经FDA验证的药物库 L1021-04 250ul/孔（10mM 溶液）/带盖96孔板 0.00 -20°C 操作手册
1 1 常温
-
营销中心
-
注意事项
保存建议 厂家推荐蓝冰运输。当您收到产品后，按照说明书建议保存于-20°C。 -
FAQ
-
1. James M. Havrilla, Cong Liu, et al. "PhenCards: a data resource linking human phenotype information to biomedical knowledge." Genome Med. 2021 May 25;13(1):91. PMID:34034817
2. Gur D, Chitlaru T, Mamroud E, et al. "Screening of an FDA-Approved Library for Novel Drugs against Y. pestis." Antibiotics (Basel). 2021 Jan 3;10(1):40. PMID:33401634
3. Moore JA, Meakin M, et al. "Effects of Caspofungin, Tolcapone, and Other FDA-Approved Medications on MRSA Susceptibility to Vancomycin." J Glob Antimicrob Resist. 2020;S2213-7165(20)30078-3. PMID:32247076
4. Turner TH, Alzubi MA, et al. "Identification of synergistic drug combinations using breast cancer patient-derived xenografts." Sci Rep. 2020 Jan 30;10(1):1493. PMID:32001757
5. Yang JJ, Han Y, et al. "Streamlined MRM method transfer between instruments assisted with HRMS matching and retention-time prediction." Anal Chim Acta. 2020;1100:88–96. PMID:31987156
在线留言
如果您对我们的产品感兴趣，请留下您的信息，我们将尽快与您联系，谢谢！
艾维缔官网
艾德官网
B站IVDSHOW
抖音军哥聊表观
视频号艾维缔
小红书艾维缔
快手表观盒子
表观遗传学
联系我们
